<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap6" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>6</ChapterID>
          <ChapterNumber>Chapter 6</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_6</ChapterDOI>
          <ChapterSequenceNumber>6</ChapterSequenceNumber>
          <ChapterTitle Language="En">Androgen Receptor Antagonists</ChapterTitle>
          <ChapterFirstPage>71</ChapterFirstPage>
          <ChapterLastPage>81</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Howard</GivenName>
                <GivenName>C.</GivenName>
                <FamilyName>Shen</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Mary-Ellen</GivenName>
                <FamilyName>Taplin</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_6" CorrespondingAffiliationID="Aff1_6">
              <AuthorName DisplayOrder="Western">
                <GivenName>Steven</GivenName>
                <GivenName>P.</GivenName>
                <FamilyName>Balk</FamilyName>
              </AuthorName>
              <Contact>
                <Email>sbalk@bidmc.harvard.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_6">
              <OrgDivision>Department of Medicine, Beth Israel Deaconess Medical Center</OrgDivision>
              <OrgName>Harvard Medical School</OrgName>
              <OrgAddress>
                <City>Boston</City>
                <State>MA</State>
                <Postcode>02215</Postcode>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_6" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Androgen receptor (AR) antagonists used clinically include steroidal (cyproterone acetate) and nonsteroidal antagonists (bicalutamide, flutamide, and nilutamide), with the latter nonsteroidal compounds being the only ones in general use in the United States. AR antagonists are used as single agents or in conjunction with surgical or medical castration (combined androgen blockade) for the initial systemic treatment of prostate cancer (CaP). AR antagonists are somewhat less effective than castration but may be preferred in some patients due to potentially fewer side effects. Combined androgen blockade is more effective than castration alone based on rapid declines in serum prostate-specific antigen (PSA) levels and the lower nadir PSA levels, but this translates into only a very small survival advantage. Patients treated with single or combined therapies invariably relapse with CaP that has been termed castration-resistant prostate cancer (CRPC). Significantly, the AR is expressed at high levels and is transcriptionally active in most cases of CRPC, and a subset of these CRPC patients respond to AR antagonist treatment. However, these responses are generally partial and transient. Molecular mechanisms that contribute to AR reactivation in CRPC and impair the activity of AR antagonists are described in this chapter. Understanding these mechanisms is critical for the development of strategies to overcome resistance and for the generation of more effective AR antagonists.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Androgen receptor</Keyword>
            <Keyword>Steroid</Keyword>
            <Keyword>Steroid receptor</Keyword>
            <Keyword>Testosterone</Keyword>
            <Keyword>Dihydrotestosterone</Keyword>
            <Keyword>Antagonist</Keyword>
            <Keyword>Bicalutamide</Keyword>
            <Keyword>Flutamide</Keyword>
            <Keyword>Nilutamide</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1">
            <Heading>Steroidal and Nonsteroidal AR Antagonists</Heading>
            <Para TextBreak="No">Androgen receptor (AR) antagonists used clinically for prostate cancer (CaP) include steroidal (cyproterone acetate) and nonsteroidal antagonists (flutamide, nilutamide, and bicalutamide), which all function as competitive inhibitors of AR binding to endogenous androgens (testosterone and dihydrotestosterone, DHT) (Fig. <InternalRef RefID="Fig1">6.1</InternalRef>). The nonsteroidal compounds are the only ones that have been in general use in the United States, but cyproterone acetate has been used extensively in other countries. The disadvantages of steroidal antagonists include lack of specificity, with cyproterone acetate being an agonist for the progesterone receptor that can suppress gonadotropin release when used as a single agent [<CitationRef CitationID="CR1_6">1</CitationRef>]. Steroidal AR antagonists such as cyproterone acetate and mifepristone also have partial agonist activity, which may limit their ability to suppress AR activity [<CitationRef CitationID="CR2_6">2</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 6.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Structures of DHT and AR antagonists</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_6">
                  <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_6_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">The nonsteroidal AR antagonists in clinical use (flutamide, nilutamide, and bicalutamide) are all chemically related (substituted toluidides) [<CitationRef CitationID="CR3_6">3</CitationRef>, <CitationRef CitationID="CR4_6">4</CitationRef>], and do not interact with other steroid receptors. Moreover, they function as relatively pure AR antagonists, although hydroxyflutamide (the active metabolite of flutamide) and nilutamide have some weak agonist activity at high concentrations. Flutamide is rapidly metabolized in vivo to hydroxyflutamide, which has about a tenfold higher affinity for AR compared to flutamide [<CitationRef CitationID="CR4_6">4</CitationRef>, <CitationRef CitationID="CR5_6">5</CitationRef>]. Nilutamide is an analogue of flutamide, and its affinity for AR is approximately the same as that of hydroxyflutamide [<CitationRef CitationID="CR6_6">6</CitationRef>]. Nilutamide has a longer half-life than flutamide; so it can be administered once per day (150–300 mg) as against the standard flutamide dose of 250 mg three times per day. The side effects of both drugs include diarrhea, nausea, and rarely hepatotoxicity, but nilutamide also frequently causes decreased darkness adaptation and rarely severe interstitial pneumonitis, which have limited its use [<CitationRef CitationID="CR7_6">7</CitationRef>]. Bicalutamide is administered as a mixture of two isomers, with the R-isomer having both the longest in vivo half-life and highest affinity for AR (about fourfold higher affinity than hydroxyflutamide) [<CitationRef CitationID="CR8_6">8</CitationRef>]. Due to its higher affinity, longer half-life (allowing once per day dosing of 50 mg), and more favorable side effect profile, bicalutamide has become the most commonly used AR antagonist. However, it should be emphasized that all of these compounds are still relatively weak AR antagonists, with the affinity of bicalutamide for the AR being ∼50-fold lower than that of DHT in direct radioactive ligand competition binding assays [<CitationRef CitationID="CR9_6">9</CitationRef>]. Moreover, in cellular transcription assays, ∼1,000-fold excess of bicalutamide is required to inhibit AR activation by DHT [<CitationRef CitationID="CR10_6">10</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Mechanisms of AR Antagonist Action</Heading>
            <Section2 ID="Sec3">
              <Heading>AR Activation by Agonist Binding</Heading>
              <Para TextBreak="No">The AR is a steroid receptor member of the large nuclear receptor superfamily. Similar to other steroid/nuclear receptors, the AR has an N-terminal domain (NTD) that mediates transcriptional activity, a C-terminal domain that binds androgen and can also stimulate transcription (ligand binding domain, LBD), a central domain that mediates sequence-specific DNA binding (DNA binding domain, DBD), and a hinge region between the DBD and LBD that regulates AR nuclear localization and degradation [<CitationRef CitationID="CR11_6">11</CitationRef>]. In contrast to other steroid/nuclear receptors, the AR NTD is larger and makes a major contribution to transcriptional activity through recruitment of multiple coactivator proteins.</Para>
              <Para TextBreak="No">The overall structure of steroid receptor LBDs, with 12 α-helices, and the way their structures are altered by ligand binding are very similar. In the absence of ligand, the AR associates with heat shock protein 90 (Hsp90) and a complex of additional chaperone proteins, which maintain AR in a conformation that permits ligand binding. Binding of agonist ligands (testosterone or DHT) shifts the position of the most C-terminal helix (helix 12), which moves towards a surface generated by helices 3–5. This movement of helix 12 has two consequences: First, it caps the steroid binding pocket to prevent the release of the bound testosterone or DHT, resulting in a slow off rate for agonist binding and a very high overall binding affinity. Second, helices 3–5, and 12 combine to generate a hydrophobic cleft (the coactivator binding site) that can bind transcriptional coactivator proteins via leucine-X-X-leucine-leucine (LXXLL) motif containing peptides. Multiple copies of the LXXLL motif (also termed nuclear receptor boxes or NR boxes) are found in the p160 family of coactivator proteins (SRC-1–3) and in several other proteins that contribute to the transcriptional activity. The agonist-liganded AR then binds as a dimer to specific DNA sequences in androgen-regulated genes (termed androgen responsive elements or AREs), where it recruits multiple coactivator and chromatin modifying proteins and ultimately RNA polymerase II, resulting in gene expression.</Para>
              <Para TextBreak="No">A further unique feature of AR is that its coactivator binding site, generated by helices 3–5, and 12, has a relatively low affinity for the LXXLL motifs found in most coactivator proteins. Instead, the AR coactivator binding site is specialized for binding to an LXXLL-like motif in the NTD (amino acids 23–27, FQNLF), and this interaction between the AR NTD and LBD further stabilizes helix 12 in the agonist position and ligand binding [<CitationRef CitationID="CR12_6">12</CitationRef>–<CitationRef CitationID="CR15_6">15</CitationRef>]. As a result of this reduced affinity of the AR LBD for LXXLL motif peptides, the AR NTD plays a more substantial role in the recruitment of transcriptional coactivator proteins (including the p160 coactivators that can interact with both the AR NTD and LBD).</Para>
            </Section2>
            <Section2 ID="Sec4">
              <Heading>Structural Changes in AR Mediated by Antagonist Binding</Heading>
              <Para TextBreak="No">All characterized steroidal and nonsteroidal AR antagonists bind to the steroid binding pocket in the LBD and function as competitive inhibitors of androgen binding. Significantly, crystal structures of the wild-type AR bound to antagonists have not yet been successfully generated. However, certain mutations in the AR LBD can convert AR antagonists into agonists, and crystal structures of these antagonist-liganded mutant AR LBDs have been obtained [<CitationRef CitationID="CR16_6">16</CitationRef>–<CitationRef CitationID="CR20_6">20</CitationRef>]. Moreover, crystal structures of other steroid receptors bound to antagonists can be used to model AR. Overall, these studies reveal two general mechanisms by which antagonists may inhibit AR transcriptional activity.</Para>
              <Para TextBreak="No">One mechanism is by distortion of the ligand-binding pocket. Binding of hydroxyflutamide (HF, the active metabolite of flutamide) forces repositioning of a threonine residue at codon 877 in the ligand-binding pocket. This is presumed to distort the LBD, preventing the movement of helix 12 into the agonist position and the generation of the coactivator binding site. Indeed, the HF liganded AR LBD does not bind to LXXLL motif containing coactivators and does not interact with the FQNLF peptide in the AR NTD. A threonine to alanine mutation in codon 877 can generate increased space to accommodate HF binding, so the T877A mutant AR is strongly stimulated by HF (but not by bicalutamide). Significantly, this T877A mutation is found with increased frequency in CRPC patients who were treated initially with flutamide [<CitationRef CitationID="CR21_6">21</CitationRef>] (see below). Nilutamide and cyproterone acetate appear to function in a manner similar to HF by distorting the ligand binding pocket, and their agonist activity is enhanced by T877A and related mutations.</Para>
              <Para TextBreak="No">Bicalutamide still inhibits the T877A mutant AR, but an AR with a tryptophan 741 to leucine mutation is strongly stimulated by bicalutamide. This W741L mutation has also been identified in patients treated with bicalutamide and in LNCaP cells adapted to grow in the presence of bicalutamide [<CitationRef CitationID="CR22_6">22</CitationRef>, <CitationRef CitationID="CR23_6">23</CitationRef>]. The crystal structure of the bicalutamide-liganded W741L mutant AR LBD indicates that bicalutamide makes direct contact with this residue, and likely forces tryptophan (in the wild-type AR) to move into a position where it directly or indirectly prevents the appropriate positioning of helix 12 [<CitationRef CitationID="CR24_6">24</CitationRef>] (Fig. <InternalRef RefID="Fig2">6.2</InternalRef>). As mentioned above for HF, the bicalutamide-liganded wild-type AR LBD cannot effectively recruit coactivator proteins or mediate binding of the AR NTD [<CitationRef CitationID="CR10_6">10</CitationRef>].<Figure Category="Standard" Float="Yes" ID="Fig2">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 6.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Structure of bicalutamide-liganded W741L mutant AR versus DHT-liganded wild-type AR. The substitution of leucine for tryptophan at residue 741 allows bicalutamide to bind and helix 12 to fold into the agonist position. In contrast, based on the positioning of tryptophan in the wild-type DHT-liganded AR (<Emphasis Type="Italic">inset</Emphasis>), it appears that bicalutamide binding to the wild-type AR would force the repositioning of tryptophan 741 and either distort helix 4 or directly interfere with helix 12</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO2_6">
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_6_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">A second mechanism of antagonism is best exemplified by the tamoxifen and raloxifene liganded ERα. Rather than distorting the steroid binding pocket, crystal structures of the tamoxifen- and raloxifene-liganded ERα show that bulky side groups of these drugs stick out from the ligand-binding pocket and directly block the surface that would be occupied by helix 12 in response to agonists, forcing helix 12 into alternative nonagonist positions [<CitationRef CitationID="CR25_6">25</CitationRef>, <CitationRef CitationID="CR26_6">26</CitationRef>]. As a result, the LXXLL motif-binding cleft is not generated, and the ERα does not effectively recruit coactivator proteins. With respect to AR, this is the likely mechanism for antagonism by mifepristone, which is also an antagonist for the glucocorticoid and progesterone receptors [<CitationRef CitationID="CR27_6">27</CitationRef>], and for a recently synthesized AR antagonist [<CitationRef CitationID="CR28_6">28</CitationRef>].</Para>
              <Para TextBreak="No">As noted above, an important consequence of agonist-induced positioning of helix 12 is that it caps the ligand-binding pocket, which prevents ligand dissociation and thereby increases the affinity for agonist ligands. In contrast, it is presumed that the alternative positioning of helix 12 in response to antagonists does not stabilize antagonist binding, resulting in a more rapid dissociation rate and lower overall affinity for the antagonist. Significantly, this fundamental difference in agonist- versus antagonist-induced positioning of helix 12 may limit the ability to develop potent competitive antagonists for testosterone and DHT.</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Role of Transcriptional Corepressors in AR Antagonist Action</Heading>
              <Para TextBreak="No">In the absence of ligand, nonsteroidal nuclear receptors such as thyroid and retinoid receptors repress transcription by recruiting the corepressor proteins NCoR and SMRT, which are associated with histone deacetylase 3. Binding of these corepressor proteins is mediated by extended LXXLL-like motifs (L-X-X-I/H-I-X-X-X-L/I), termed corepressor nuclear receptor boxes (CoRNR boxes), which are located in the C-terminal half of NCoR and SMRT. The positioning of helix 12 away from helices 3 to 5 in unliganded nuclear receptors opens the LXXLL site to accommodate these larger CoRNR boxes, which make three helical turns (versus two turns for LXXLL motifs). While the nonsteroidal nuclear receptors bind DNA in the absence of ligand and actively repress transcription via NCoR and SMRT recruitment, DNA binding by steroid receptors is generally ligand-dependent and mediated physiologically by agonist ligands. Nonetheless, certain steroid hormone receptor antagonists (or partial agonists) can stimulate DNA binding and recruitment of NCoR or SMRT. This appears to contribute to the action of the ERα antagonists tamoxifen and raloxifene. As noted above, the crystal structures of the tamoxifen- and raloxifene-liganded ERα show that the side groups of these drugs force alternative nonagonist positions for helix 12 [<CitationRef CitationID="CR25_6">25</CitationRef>, <CitationRef CitationID="CR26_6">26</CitationRef>]. In addition to impairing recruitment of coactivator proteins, this repositioning of helix 12 allows corepressor binding. Significantly, the tissue-selective activities of these drugs (antagonists in breast cancer and agonists in bone and other tissues) appear to reflect the relative levels of transcriptional coactivators versus corepressors in the respective tissues [<CitationRef CitationID="CR29_6">29</CitationRef>]. Biochemical studies of mifepristone similarly indicate that its antagonist activity against the glucocorticoid and progesterone receptors as well as AR is enhanced by the recruitment of NCoR or SMRT [<CitationRef CitationID="CR30_6">30</CitationRef>–<CitationRef CitationID="CR34_6">34</CitationRef>].</Para>
              <Para TextBreak="No">In contrast to other steroid receptors, the agonist-liganded AR interacts with NCoR and SMRT [<CitationRef CitationID="CR35_6">35</CitationRef>–<CitationRef CitationID="CR37_6">37</CitationRef>]. The interaction between AR and these corepressors is complex as NCoR and SMRT interact with both the AR LBD (via CoRNR boxes) and the AR NTD (via direct interactions and indirectly through an adaptor protein, TAB2) (see below) [<CitationRef CitationID="CR34_6">34</CitationRef>, <CitationRef CitationID="CR36_6">36</CitationRef>, <CitationRef CitationID="CR38_6">38</CitationRef>, <CitationRef CitationID="CR39_6">39</CitationRef>]. Moreover, RNAi approaches have shown that NCoR and SMRT function at physiological levels as negative regulators of androgen stimulated AR transcriptional activity [<CitationRef CitationID="CR34_6">34</CitationRef>, <CitationRef CitationID="CR40_6">40</CitationRef>, <CitationRef CitationID="CR41_6">41</CitationRef>]. AR recruitment of NCoR, as assessed by chromatin immunoprecipitation (ChIP), is increased by AR antagonists or partial agonists including bicalutamide, hydroxyflutamide, and cyproterone acetate, although mifepristone appears to mediate more robust NCoR/SMRT recruitment [<CitationRef CitationID="CR33_6">33</CitationRef>, <CitationRef CitationID="CR34_6">34</CitationRef>]. Consistent with NCoR/SMRT recruitment, downregulation of these corepressors by RNAi or other mechanisms can increase the agonist activity of AR antagonists such as hydroxyflutamide that have partial agonist activity [<CitationRef CitationID="CR34_6">34</CitationRef>, <CitationRef CitationID="CR40_6">40</CitationRef>, <CitationRef CitationID="CR42_6">42</CitationRef>–<CitationRef CitationID="CR45_6">45</CitationRef>]. Loss of NCoR/SMRT may also stimulate the agonist activity of the bicalutamide-liganded AR, though additional factors may be required to augment coactivator activity (see below).</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Clinical Applications of AR Antagonists in CaP</Heading>
            <Para TextBreak="No">AR antagonists are used as single agents or in conjunction with suppression of testicular androgen synthesis (surgical castration or medical castration by administration of an LHRH superagonist) for the initial systemic treatment of CaP. AR antagonists are also used in CaP that recurs after initial castration therapy. These recurrent tumors have been termed hormone refractory, androgen-independent, or castration-resistant prostate cancers (CRPC), the latter being the currently preferred term as it does not have mechanistic implications. However, as outlined below, the efficacy of AR antagonists in each of these settings and how their use may be optimized remain as important questions.</Para>
            <Section2 ID="Sec7">
              <Heading>AR Antagonist Monotherapy in Previously Untreated Patients</Heading>
              <Para TextBreak="No">Flutamide (with or without finasteride) and nilutamide as single agents have efficacy in previously untreated CaP but have not been directly compared to castration in clinical trials and are not commonly prescribed as monotherapy. Bicalutamide at a standard dose (50 mg/day) is less effective than castration, and at a higher dose (150 mg/day) it was less effective than castration in terms of survival in men with metastatic CaP [<CitationRef CitationID="CR46_6">46</CitationRef>]. In contrast, bicalutamide at 150 mg/day appears to be equivalent to castration in terms of time to progression and overall mortality in previously untreated men with nonmetastatic locally advanced disease [<CitationRef CitationID="CR47_6">47</CitationRef>, <CitationRef CitationID="CR48_6">48</CitationRef>]. Another trial compared initial bicalutamide monotherapy (150 mg/day) and castration at disease progression with up front combined goserelin plus flutamide and found no difference in disease-specific or overall mortality [<CitationRef CitationID="CR49_6">49</CitationRef>]. However, an unexplained increase in overall mortality was observed in a subgroup that was treated only with bicalutamide. Further studies of 150 mg/day bicalutamide versus primary therapy (radical prostatectomy, radiation, or watchful waiting) in men with early stage CaP showed no improvement in progression-free survival for the bicalutamide group, and a small increase in nonprostate-specific mortality was observed in the bicalutamide versus watchful waiting group [<CitationRef CitationID="CR50_6">50</CitationRef>]. Bicalutamide monotherapy has not been approved by the U.S. Food and Drug Administration for use in CaP but is commonly prescribed outside the U.S.</Para>
              <Para TextBreak="No">While AR antagonists as single agents appear inferior to castration, particularly in men with more advanced CaP, they have advantages with respect to side effects. Recent studies have clearly established the negative metabolic consequences of castration, which include weight gain, increased cardiovascular mortality, bone and muscle loss, and glucose intolerance [<CitationRef CitationID="CR51_6">51</CitationRef>, <CitationRef CitationID="CR52_6">52</CitationRef>]. In contrast, these effects are not observed in patients treated with single agent nonsteroidal antagonists [<CitationRef CitationID="CR53_6">53</CitationRef>, <CitationRef CitationID="CR54_6">54</CitationRef>]. This likely reflects the differences in effects on steroid hormone levels, with testosterone and estradiol being decreased in response to castration versus modestly increased in patients treated with nonsteroidal AR antagonists (GnRH levels are decreased by cyproterone acetate due to its progestin activity). In some patients, the maintained or increased sex steroid levels after treatment with nonsteroidal AR antagonists, possibly in conjunction with lower CNS levels of these drugs, also results in less loss of libido and sexual function compared to castration.</Para>
            </Section2>
            <Section2 ID="Sec8">
              <Heading>Combined Castration and AR Antagonist Therapy (Combined Androgen Blockade, CAB)</Heading>
              <Para TextBreak="No">The pioneering work of Huggins and others showed that bilateral surgical adrenalectomy or hypophysectomy to ablate adrenal androgen production resulted in objective responses in about one-third of patients and pain relief in more than two-third of them. This surgical approach to ablate adrenal androgens was later replaced by medical adrenalectomy with aminoglutethimide or ketoconazole (both suppress adrenal androgen synthesis), which yielded similar results. While most responses to suppression or ablation of adrenal androgen production in CRPC were partial and transient, they suggested that adrenal androgens were providing some stimulus for CRPC and that blocking adrenal androgens at an earlier stage may be beneficial. This led to a series of clinical trials that compared castration alone (orchiectomy or LHRH superagonist monotherapy) versus castration plus an AR antagonist (flutamide, bicalutamide, cyproterone acetate, or nilutamide) to block AR stimulation by residual adrenal androgens (combined androgen blockade, CAB).</Para>
              <Para TextBreak="No">Although the combined therapies resulted in more rapid responses and lower nadir PSA levels, the results of the largest trial and meta-analyses of the multiple other trials showed that the addition of AR antagonists caused only a very small (approximately 2%) improvement in survival [<CitationRef CitationID="CR55_6">55</CitationRef>, <CitationRef CitationID="CR56_6">56</CitationRef>]. Importantly, the conclusion that can be drawn from these studies is that the available AR antagonists do not have substantial activity against the tumor cells that survive castration and emerge as CRPC. Consistent with this conclusion, the majority of CRPC that occur after orchiectomy or LHRH superagonist monotherapy do not respond to secondary treatments with AR antagonists, including high dose therapy (150–200 mg/day) with bicalutamide (see below) [<CitationRef CitationID="CR57_6">57</CitationRef>–<CitationRef CitationID="CR59_6">59</CitationRef>]. The efficacy of CAB will need to be readdressed as more effective AR antagonists or other approaches to suppress AR activity are developed (see below).</Para>
            </Section2>
            <Section2 ID="Sec9">
              <Heading>AR Antagonist Withdrawal Responses</Heading>
              <Para TextBreak="No">Responses to the withdrawal of nonsteroidal AR antagonists were first observed when flutamide was discontinued in patients who relapsed after combined castration plus flutamide treatment [<CitationRef CitationID="CR60_6">60</CitationRef>, <CitationRef CitationID="CR61_6">61</CitationRef>], and have since been documented for withdrawal of bicalutamide and nilutamide [<CitationRef CitationID="CR62_6">62</CitationRef>–<CitationRef CitationID="CR65_6">65</CitationRef>]. In a recent multi-institutional prospective trial, withdrawal responses (&gt;50% decline in PSA) were observed in 24, 13, and 25% of patients after discontinuing flutamide, bicalutamide, and nilutamide, respectively [<CitationRef CitationID="CR66_6">66</CitationRef>]. Median progression-free survival was only 3 months, but prolonged responses (&gt;1 year) were observed in 19% of responders. Longer duration of AR antagonist use was a predictor of response and progression-free survival.</Para>
              <Para TextBreak="No">The molecular basis for these withdrawal responses remains unclear but likely reflects multiple adaptations by the tumor cells that can enhance the partial agonist activities of these antagonists, including mutations in the AR LBD (see below). Interestingly, two studies found that withdrawal responses could be enhanced by suppression of adrenal androgen synthesis, suggesting that adrenal androgens (or intratumoral synthesized androgens, see below) are stimulating all or a subset of tumor cells in these patients after AR antagonist withdrawal [<CitationRef CitationID="CR67_6">67</CitationRef>, <CitationRef CitationID="CR68_6">68</CitationRef>]. However, a randomized trial comparing anti-androgen withdrawal combined with adrenal androgen suppression (ketoconazole/hydrocortisone) to sequential anti-androgen withdrawal followed by adrenal androgen suppression at progression demonstrated no significant clinical benefits [<CitationRef CitationID="CR68_6">68</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec10">
              <Heading>AR Antagonists in CRPC</Heading>
              <Para TextBreak="No">AR and AR-regulated genes are still expressed at high levels in CRPC, indicating that AR transcriptional activity is reactivated in these tumors and that AR remains a therapeutic target [<CitationRef CitationID="CR69_6">69</CitationRef>–<CitationRef CitationID="CR73_6">73</CitationRef>]. Consistent with this conclusion, patients with CRPC who were not treated with an AR antagonist during their initial androgen deprivation therapy may respond to treatment with an AR antagonist (or to a switch to another AR antagonist), though response rates (&gt;50% PSA decline) are generally low (15–40%) and transient (3–6 months) [<CitationRef CitationID="CR58_6">58</CitationRef>, <CitationRef CitationID="CR59_6">59</CitationRef>, <CitationRef CitationID="CR74_6">74</CitationRef>, <CitationRef CitationID="CR75_6">75</CitationRef>]. Understanding why AR antagonists do not substantially enhance responses to castration therapy in the initial therapy of CaP and why these drugs are relatively ineffective in CRPC is clearly critical for the development of more effective AR antagonists. Therefore, the section below outlines mechanisms that may contribute to their loss of function in CRPC.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>Mechanism Mediating AR Reactivation and Resistance to AR Antagonists in CRPC</Heading>
            <Section2 ID="Sec12">
              <Heading>Increased AR Expression</Heading>
              <Para TextBreak="No">AR mRNA is consistently increased in CRPC (though protein levels may be more variable) with AR gene amplification in approximately one-third of cases [<CitationRef CitationID="CR70_6">70</CitationRef>, <CitationRef CitationID="CR72_6">72</CitationRef>, <CitationRef CitationID="CR73_6">73</CitationRef>, <CitationRef CitationID="CR76_6">76</CitationRef>, <CitationRef CitationID="CR77_6">77</CitationRef>]. Increased AR protein would presumably amplify residual AR activity and may enhance the agonist activity of bicalutamide by unclear mechanisms [<CitationRef CitationID="CR78_6">78</CitationRef>]. A recent study investigated bicalutamide resistance in C4–2 cells, which are derived from a LNCaP xenograft that relapsed after castration. Bicalutamide did not have AR agonist activity in these cells, but it was unable to inhibit basal AR NTD transcriptional activity, suggesting that uncoupling of the NTD from inhibition by the LBD (by unclear mechanisms) may contribute to bicalutamide resistance in CRPC [<CitationRef CitationID="CR79_6">79</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec13">
              <Heading>Expression of Antagonist Activated Mutant ARs</Heading>
              <Para TextBreak="No">
                <Emphasis Type="Italic">AR</Emphasis> mutations identified in CRPC can enhance AR activation by weak androgens, other steroid hormones, or AR antagonists [<CitationRef CitationID="CR77_6">77</CitationRef>, <CitationRef CitationID="CR80_6">80</CitationRef>]. While the overall frequency of <Emphasis Type="Italic">AR</Emphasis> mutations in patients treated with castration alone was low [<CitationRef CitationID="CR22_6">22</CitationRef>], mutant ARs that were stimulated by hydroxyflutamide were more frequent (∼one-third of cases) in patients who relapsed after combined androgen blockade with flutamide, indicating that there is positive selection for these mutations [<CitationRef CitationID="CR21_6">21</CitationRef>]. Moreover, these flutamide-activated mutant ARs are still inhibited by bicalutamide, and patients who relapse with CRPC after combined castration plus flutamide therapy have increased responses to bicalutamide [<CitationRef CitationID="CR21_6">21</CitationRef>, <CitationRef CitationID="CR58_6">58</CitationRef>, <CitationRef CitationID="CR59_6">59</CitationRef>]. A mutant AR (W741C) that is activated by bicalutamide has also been found in patients treated with bicalutamide [<CitationRef CitationID="CR22_6">22</CitationRef>] and in LNCaP CaP cells adapted to grow in the presence of bicalutamide [<CitationRef CitationID="CR23_6">23</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec14">
              <Heading>Increased Intratumoral Androgen Synthesis</Heading>
              <Para TextBreak="No">Direct measurements of intraprostatic androgens in castrated men with locally recurrent CRPC have shown that levels are increased compared to those in prostate soon after castration and are not significantly lower than levels prior to castration, indicating that increased testosterone uptake or synthesis by tumor cells may be a mechanism for reactivation of AR activity [<CitationRef CitationID="CR71_6">71</CitationRef>, <CitationRef CitationID="CR81_6">81</CitationRef>, <CitationRef CitationID="CR82_6">82</CitationRef>]. Moreover, a recent study has found that testosterone levels in metastatic CRPC samples are actually higher than in prostate from eugonadal men, despite castrate levels of serum androgens [<CitationRef CitationID="CR73_6">73</CitationRef>]. Gene expression studies in CRPC have revealed increased levels of multiple enzymes that mediate synthesis of weak androgens (DHEA and androstenedione) from cholesterol (including CYP17A), and enzymes mediating synthesis of testosterone and DHT from weak androgens [<CitationRef CitationID="CR70_6">70</CitationRef>, <CitationRef CitationID="CR72_6">72</CitationRef>, <CitationRef CitationID="CR73_6">73</CitationRef>, <CitationRef CitationID="CR83_6">83</CitationRef>]. Importantly, the efficacy of AR antagonists, which are weak competitive inhibitors of testosterone and DHT binding, would clearly be impaired by high levels of intracellular androgens. The synthesis of weak androgens (by the adrenals and, presumably, the tumor cells) can be suppressed by CYP17A inhibitors including ketoconazole and by a more potent inhibitor, abiraterone, which is currently in phase III clinical trials [<CitationRef CitationID="CR84_6">84</CitationRef>]. Therefore, it will be of interest to determine whether the efficacy of AR antagonists can be enhanced by these or other inhibitors of androgen synthesis.</Para>
            </Section2>
            <Section2 ID="Sec15">
              <Heading>Altered Expression of Transcriptional Coactivator Versus Corepressor Proteins</Heading>
              <Para TextBreak="No">Data from several groups indicate that expression of transcriptional coactivator proteins is increased in CRPC, which would increase residual AR activity and may enhance partial agonist activity of AR antagonists [<CitationRef CitationID="CR85_6">85</CitationRef>, <CitationRef CitationID="CR86_6">86</CitationRef>]. With respect to corepressors, NCoR and SMRT are recruited as part of a complex containing HDAC3, TBL1, TBLR1, and TAB2 [<CitationRef CitationID="CR45_6">45</CitationRef>, <CitationRef CitationID="CR87_6">87</CitationRef>–<CitationRef CitationID="CR90_6">90</CitationRef>]. TAB2 phosphorylation by MEKK1 in response to inflammatory signals has been shown to result in loss of the NCoR/HDAC3 complex from the AR and has also been reported to convert bicalutamide to an agonist [<CitationRef CitationID="CR45_6">45</CitationRef>, <CitationRef CitationID="CR91_6">91</CitationRef>]. Using RNAi approaches, we have failed to detect bicalutamide agonist activity in response to NCoR or SMRT downregulation [<CitationRef CitationID="CR41_6">41</CitationRef>], but loss of NCoR via the MEKK1/TAB2 mechanism versus NCoR downregulation by siRNA may result in functionally distinct complexes, with MEKK1 possibly having additional effects that enhance coactivator recruitment by the bicalutamide-liganded AR. In any case, further analyses of links between inflammation and AR antagonist resistance are clearly warranted.</Para>
            </Section2>
            <Section2 ID="Sec16">
              <Heading>Enhanced Responses to Low Androgen Levels Mediated by Activation of Kinase Signaling Pathways</Heading>
              <Para TextBreak="No">Studies in cell culture and xenografts indicate that CaP cells can adapt to markedly enhance their responses to low (subnanomolar) androgen concentrations, which would presumably increase their resistance to weak competitive AR antagonists. This AR hypersensitivity may occur in response to activation of certain kinases, including protein kinase A, ErbB2, Ras, c-Src, Cdk1, and the PI3 kinase/Akt pathway. The molecular basis for AR activation by these kinases is unclear but may include direct phosphorylation of AR or coactivator proteins. Further studies are needed to determine the extent to which these pathways contribute to AR activation and antagonist resistance in CRPC.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec17">
            <Heading>New AR Antagonists and Future Directions</Heading>
            <Para TextBreak="No">While it may be possible to enhance the efficacy of available AR antagonists by targeting one or more of the mechanisms outlined above, it seems clear that there is a need for new AR antagonists that are more potent or function by novel mechanisms. BMS 641988 represents a chemically novel class of nonsteroidal AR antagonists [<CitationRef CitationID="CR92_6">92</CitationRef>]. This compound is ∼tenfold more potent than bicalutamide and is currently in phase I evaluation. MDV3100 is a nonsteroidal AR antagonist that functions by a novel mechanism (blocking nuclear transport), and it is about to enter phase III testing. Additional promising approaches are the development of antagonists that enhance AR degradation [<CitationRef CitationID="CR93_6">93</CitationRef>] or recruitment of corepressor proteins [<CitationRef CitationID="CR33_6">33</CitationRef>, <CitationRef CitationID="CR34_6">34</CitationRef>, <CitationRef CitationID="CR94_6">94</CitationRef>].</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_6.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_6">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Isurugi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Fukutani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Ishida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hosoi</FamilyName>
                </BibAuthorName>
                <Year>1980</Year>
                <ArticleTitle Language="En">Endocrine effects of cyproterone acetate in patients with prostatic cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>123</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>180</FirstPage>
                <LastPage>183</LastPage>
                <Occurrence Type="PID">
                  <Handle>7354512</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL3c7hvVSgug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Isurugi K, Fukutani K, Ishida H, Hosoi Y. Endocrine effects of cyproterone acetate in patients with prostatic cancer. J Urol 1980; 123(2):180–183.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_6">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Kemppainen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MV</Initials>
                  <FamilyName>Lane</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>267</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>968</FirstPage>
                <LastPage>974</LastPage>
                <Occurrence Type="PID">
                  <Handle>1730684</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38Xns1KnsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 1992; 267(2):968–974.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_6">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Dalton</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands</ArticleTitle>
                <JournalTitle>Pharm Res</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1641</FirstPage>
                <LastPage>1658</LastPage>
                <Occurrence Type="PID">
                  <Handle>16841196</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s11095-006-9024-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XnvVymsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res 2006; 23(8):1641–1658.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_6">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Yin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Perera</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SS</Initials>
                  <FamilyName>Hong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Marhefka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Stourman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>211</FirstPage>
                <LastPage>223</LastPage>
                <Occurrence Type="PID">
                  <Handle>12488554</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1124/mol.63.1.211</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjsVOr</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N et al. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 2003; 63(1):211–223.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_6">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Schulz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Schmoldt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Donn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Becker</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment</ArticleTitle>
                <JournalTitle>Eur J Clin Pharmacol</JournalTitle>
                <VolumeID>34</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>633</FirstPage>
                <LastPage>636</LastPage>
                <Occurrence Type="PID">
                  <Handle>3169114</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00615229</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1M%2FgsFehsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schulz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 1988; 34(6):633–636.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_6">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Creaven</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Pendyala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Tremblay</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Pharmacokinetics and metabolism of nilutamide</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>37</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>13</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>1992598</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0090-4295(91)80096-P</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M7is12gsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Creaven PJ, Pendyala L, Tremblay D. Pharmacokinetics and metabolism of nilutamide. Urology 1991; 37(Suppl 2):13–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_6">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Janknegt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Abbou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bartoletti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Bernstein-Hahn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Bracken</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Brisset</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>149</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>77</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>7678043</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s7gvVGmsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149(1):77–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_6">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mukherjee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Kirkovsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>XT</Initials>
                  <FamilyName>Yao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Yates</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Dalton</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Enantioselective binding of Casodex to the androgen receptor</ArticleTitle>
                <JournalTitle>Xenobiotica</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>117</FirstPage>
                <LastPage>122</LastPage>
                <Occurrence Type="PID">
                  <Handle>8867996</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3109/00498259609046693</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XitFShuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mukherjee A, Kirkovsky L, Yao XT, Yates RC, Miller DD, Dalton JT. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996; 26(2):117–122.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_6">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BJ</Initials>
                  <FamilyName>Furr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Tucker</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">The preclinical development of bicalutamide: pharmacodynamics and mechanism of action</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>47</VolumeID>
                <IssueID>Suppl 1A</IssueID>
                <FirstPage>13</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>8560673</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(96)80003-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK287kvFOlsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 1996; 47(Suppl 1A):13–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_6">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Masiello</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <IssueID>29</IssueID>
                <FirstPage>26321</FirstPage>
                <LastPage>26326</LastPage>
                <Occurrence Type="PID">
                  <Handle>12015321</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M203310200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsFKrtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277(29):26321–26326.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_6">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Molecular biology of the androgen receptor</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>3001</FirstPage>
                <LastPage>3015</LastPage>
                <Occurrence Type="PID">
                  <Handle>12089231</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2002.10.018</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xlslyrt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20(13):3001–3015.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_6">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Gampe</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Kole</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Hnat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TB</Initials>
                  <FamilyName>Stanley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>An</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance</ArticleTitle>
                <JournalTitle>Mol Cell</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>425</FirstPage>
                <LastPage>438</LastPage>
                <Occurrence Type="PID">
                  <Handle>15525515</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.molcel.2004.09.036</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVWhtr%2FI</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>He B, Gampe RT, Jr., Kole AJ, Hnat AT, Stanley TB, An G et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004; 16(3):425–438.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_6">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Pfaff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ES</Initials>
                  <FamilyName>Payne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Gron</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BM</Initials>
                  <FamilyName>Buehrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Fletterick</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Recognition and accommodation at the androgen receptor coactivator binding interface</ArticleTitle>
                <JournalTitle>PLoS Biol</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>E274</FirstPage>
                <Occurrence Type="PID">
                  <Handle>15328534</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1371/journal.pbio.0020274</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2004; 2(9):E274.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_6">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Estebanez-Perpina</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Mar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Delgado-Rodrigues</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Nguyen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Baxter</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>280</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>8060</FirstPage>
                <LastPage>8068</LastPage>
                <Occurrence Type="PID">
                  <Handle>15563469</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M407046200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhs1yitb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Estebanez-Perpina E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD et al. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 2005; 280(9):8060–8068.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_6">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Kemppainen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>275</VolumeID>
                <IssueID>30</IssueID>
                <FirstPage>22986</FirstPage>
                <LastPage>22994</LastPage>
                <Occurrence Type="PID">
                  <Handle>10816582</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M002807200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXltlGqs7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 2000; 275(30):22986–22994.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_6">
              <CitationNumber>16.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Matias</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Donner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Coelho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Thomaz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Peixoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Macedo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>275</VolumeID>
                <IssueID>34</IssueID>
                <FirstPage>26164</FirstPage>
                <LastPage>26171</LastPage>
                <Occurrence Type="PID">
                  <Handle>10840043</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M004571200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmt1OksLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000; 275(34):26164–26171.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_6">
              <CitationNumber>17.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Sack</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KF</Initials>
                  <FamilyName>Kish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Attar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Kiefer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>An</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>98</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>4904</FirstPage>
                <LastPage>4909</LastPage>
                <Occurrence Type="PID">
                  <Handle>11320241</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.081565498</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjt1Ogtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 2001; 98(9):4904–4909.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_6">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Marhefka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BM</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Bishop</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Kirkovsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mukherjee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Dalton</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands</ArticleTitle>
                <JournalTitle>J Med Chem</JournalTitle>
                <VolumeID>44</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>1729</FirstPage>
                <LastPage>1740</LastPage>
                <Occurrence Type="PID">
                  <Handle>11356108</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/jm0005353</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjtVKhtrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marhefka CA, Moore BM, Bishop TC, Kirkovsky L, Mukherjee A, Dalton JT et al. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem 2001; 44(11):1729–1740.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_6">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Bohl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Bell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Dalton</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Structural basis for accommodation of nonsteroidal ligands in the androgen receptor</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>280</VolumeID>
                <IssueID>45</IssueID>
                <FirstPage>37747</FirstPage>
                <LastPage>37754</LastPage>
                <Occurrence Type="PID">
                  <Handle>16129672</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M507464200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtF2isrbL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005; 280(45):37747–37754.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_6">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Bohl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Bell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Dalton</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>282</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>13648</FirstPage>
                <LastPage>13655</LastPage>
                <Occurrence Type="PID">
                  <Handle>17311914</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M611711200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXks1Ggurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 2007; 282(18):13648–13655.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_6">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YJ</Initials>
                  <FamilyName>Ko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Upton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Rajeshkumar</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2511</FirstPage>
                <LastPage>2515</LastPage>
                <Occurrence Type="PID">
                  <Handle>10363963</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjs1yms7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11):2511–2515.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_6">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Rajeshkumar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CP</Initials>
                  <FamilyName>Werner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Woda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Picus</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>2673</FirstPage>
                <LastPage>2678</LastPage>
                <Occurrence Type="PID">
                  <Handle>12860943</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.11.102</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXptlCktLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21(14):2673–2678.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_6">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Miyazaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Araki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yamaoka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Kanzaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kusaka</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>149</FirstPage>
                <LastPage>153</LastPage>
                <Occurrence Type="PID">
                  <Handle>12517791</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjvFKgsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63(1):149–153.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_6">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Bohl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Bell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Dalton</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Structural basis for antagonism and resistance of bicalutamide in prostate cancer</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>102</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>6201</FirstPage>
                <LastPage>6206</LastPage>
                <Occurrence Type="PID">
                  <Handle>15833816</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0500381102</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXkt1ClsLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 2005; 102(17):6201–6206.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_6">
              <CitationNumber>25.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Brzozowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Pike</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Dauter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Hubbard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Bonn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Engstrom</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Molecular basis of agonism and antagonism in the oestrogen receptor</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>389</VolumeID>
                <IssueID>6652</IssueID>
                <FirstPage>753</FirstPage>
                <LastPage>758</LastPage>
                <Occurrence Type="PID">
                  <Handle>9338790</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/39645</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmvVSnt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652):753–758.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_6">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Shiau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Barstad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Loria</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Kushner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Agard</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>95</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>927</FirstPage>
                <LastPage>937</LastPage>
                <Occurrence Type="PID">
                  <Handle>9875847</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0092-8674(00)81717-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjslyltQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7):927–937.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_6">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Cadepond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Ulmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EE</Initials>
                  <FamilyName>Baulieu</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">RU486 (mifepristone): mechanisms of action and clinical uses</ArticleTitle>
                <JournalTitle>Annu Rev Med</JournalTitle>
                <VolumeID>48</VolumeID>
                <FirstPage>129</FirstPage>
                <LastPage>156</LastPage>
                <Occurrence Type="PID">
                  <Handle>9046951</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1146/annurev.med.48.1.129</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhtFKqsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997; 48:129–156.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_6">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Cantin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Faucher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Couture</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KP</Initials>
                  <FamilyName>Jesus-Tran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Legrand</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Ciobanu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>282</VolumeID>
                <IssueID>42</IssueID>
                <FirstPage>30910</FirstPage>
                <LastPage>30919</LastPage>
                <Occurrence Type="PID">
                  <Handle>17711855</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M705524200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtFGgs7zM</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cantin L, Faucher F, Couture JF, Jesus-Tran KP, Legrand P, Ciobanu LC et al. Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem 2007; 282(42):30910–30919.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_6">
              <CitationNumber>29.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Shang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Molecular determinants for the tissue specificity of SERMs</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>295</VolumeID>
                <IssueID>5564</IssueID>
                <FirstPage>2465</FirstPage>
                <LastPage>2468</LastPage>
                <Occurrence Type="PID">
                  <Handle>11923541</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1068537</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XisFSksb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295(5564):2465–2468.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_6">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Jackson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Richer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Bain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Takimoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Tung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KB</Initials>
                  <FamilyName>Horwitz</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>693</FirstPage>
                <LastPage>705</LastPage>
                <Occurrence Type="PID">
                  <Handle>9171233</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.11.6.693</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjtl2kur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997; 11(6):693–705.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_6">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Schulz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eggert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Baniahmad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Dostert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Heinzel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Renkawitz</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>277</VolumeID>
                <IssueID>29</IssueID>
                <FirstPage>26238</FirstPage>
                <LastPage>26243</LastPage>
                <Occurrence Type="PID">
                  <Handle>12011091</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M203268200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsFKrtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schulz M, Eggert M, Baniahmad A, Dostert A, Heinzel T, Renkawitz R. RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J Biol Chem 2002; 277(29):26238–26243.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_6">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Wagner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Norris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Knotts</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Weigel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>McDonnell</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1369</FirstPage>
                <LastPage>1378</LastPage>
                <Occurrence Type="PID">
                  <Handle>9488452</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhtleiurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 1998; 18(3):1369–1378.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_6">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Song</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Coghlan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>70</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>14593076</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2003-0189</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjsVCisw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004; 18(1):70–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_6">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Hodgson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Astapova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Verhoeven</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Choi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>280</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>6511</FirstPage>
                <LastPage>6519</LastPage>
                <Occurrence Type="PID">
                  <Handle>15598662</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M408972200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhsV2qs7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005; 280(8):6511–6519.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_6">
              <CitationNumber>35.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Brzostek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AN</Initials>
                  <FamilyName>Hollenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1492</FirstPage>
                <LastPage>1501</LastPage>
                <Occurrence Type="PID">
                  <Handle>12089345</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.16.7.1492</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsVGitb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 2002; 16(7):1492–1501.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_6">
              <CitationNumber>36.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Dotzlaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Moehren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Cato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Iniguez Lluhi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Baniahmad</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The amino terminus of the human AR is target for corepressor action and antihormone agonism</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>661</FirstPage>
                <LastPage>673</LastPage>
                <Occurrence Type="PID">
                  <Handle>11923464</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.16.4.661</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XivVehtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA, Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 2002; 16(4):661–673.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_6">
              <CitationNumber>37.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Liao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LY</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Godavarthy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Xia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Ghosh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>278</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>5052</FirstPage>
                <LastPage>5061</LastPage>
                <Occurrence Type="PID">
                  <Handle>12441355</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M206374200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhtVKlt78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003; 278(7):5052–5061.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_6">
              <CitationNumber>38.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Dotzlaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Papaioannou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Moehren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Claessens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Baniahmad</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>213</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>79</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>15062576</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.mce.2003.10.036</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhsV2rt7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol 2003; 213(1):79–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_6">
              <CitationNumber>39.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kawate</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Ohnaka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Nawata</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Takayanagi</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Nuclear compartmentalization of N-CoR and its interactions with steroid receptors</ArticleTitle>
                <JournalTitle>Mol Cell Biol</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>6633</FirstPage>
                <LastPage>6655</LastPage>
                <Occurrence Type="PID">
                  <Handle>16914745</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1128/MCB.01534-05</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XovFygsrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wu Y, Kawate H, Ohnaka K, Nawata H, Takayanagi R. Nuclear compartmentalization of N-CoR and its interactions with steroid receptors. Mol Cell Biol 2006; 26(17):6633–6655.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_6">
              <CitationNumber>40.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HG</Initials>
                  <FamilyName>Yoon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Wong</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>20</IssueID>
                <FirstPage>1048</FirstPage>
                <LastPage>1060</LastPage>
              </BibArticle>
              <BibUnstructured>Yoon HG, Wong J. The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 2005; 20(5):1048–1060.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_6">
              <CitationNumber>41.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Hodgson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Astapova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AN</Initials>
                  <FamilyName>Hollenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>67</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>8388</FirstPage>
                <LastPage>8395</LastPage>
                <Occurrence Type="PID">
                  <Handle>17804755</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-07-0617</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXpvFKisro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007; 67(17):8388–8395.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_6">
              <CitationNumber>42.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Shang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Myers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Formation of the androgen receptor transcription complex</ArticleTitle>
                <JournalTitle>Mol Cell</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>601</FirstPage>
                <LastPage>610</LastPage>
                <Occurrence Type="PID">
                  <Handle>11931767</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1097-2765(02)00471-9</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XivVylt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9(3):601–610.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_6">
              <CitationNumber>43.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Kang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OA</Initials>
                  <FamilyName>Janne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Palvimo</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>18</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2633</FirstPage>
                <LastPage>2648</LastPage>
                <Occurrence Type="PID">
                  <Handle>15308689</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2004-0245</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpslKksro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004; 18(11):2633–2648.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_6">
              <CitationNumber>44.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Berrevoets</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Umar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trapman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AO</Initials>
                  <FamilyName>Brinkmann</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Differential modulation of androgen receptor transcriptional activity by the nuclear receptor corepressor (N-CoR)</ArticleTitle>
                <JournalTitle>Biochem J</JournalTitle>
                <VolumeID>379</VolumeID>
                <IssueID>Pt 3</IssueID>
                <FirstPage>731</FirstPage>
                <LastPage>738</LastPage>
                <Occurrence Type="PID">
                  <Handle>14744261</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1042/BJ20031456</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjsFSmsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berrevoets CA, Umar A, Trapman J, Brinkmann AO. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor corepressor (N-CoR). Biochem J 2004; 379(Pt 3):731–738.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_6">
              <CitationNumber>45.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Baek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Bourk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Ohgi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Garcia-Bassets</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sanjo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>124</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>615</FirstPage>
                <LastPage>629</LastPage>
                <Occurrence Type="PID">
                  <Handle>16469706</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.cell.2005.12.032</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhslaqsL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006; 124(3):615–629.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_6">
              <CitationNumber>46.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Tyrrell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Kaisary</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Iversen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Anderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Baert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Tammela</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>33</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>447</FirstPage>
                <LastPage>456</LastPage>
                <Occurrence Type="PID">
                  <Handle>9643663</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1159/000019634</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlsVajtro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T et al. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33(5):447–456.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_6">
              <CitationNumber>47.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Iversen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Tyrrell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Kaisary</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Anderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Poppel</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Tammela</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>164</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1579</FirstPage>
                <LastPage>1582</LastPage>
                <Occurrence Type="PID">
                  <Handle>11025708</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)67032-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M%2FjtFGqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, van Poppel H, Tammela TL et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164(5):1579–1582.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_6">
              <CitationNumber>48.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Iversen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Tyrrell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Kaisary</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Anderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Baert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Tammela</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>51</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>389</FirstPage>
                <LastPage>396</LastPage>
                <Occurrence Type="PID">
                  <Handle>9510340</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(98)00004-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1c7mvFWlsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51(3):389–396.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_6">
              <CitationNumber>49.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Boccardo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Barichello</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Battaglia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Carmignani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Comeri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Ferraris</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>42</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>481</FirstPage>
                <LastPage>490</LastPage>
                <Occurrence Type="PID">
                  <Handle>12429158</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0302-2838(02)00435-9</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXit1Wguw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferraris V et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 2002; 42(5):481–490.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_6">
              <CitationNumber>50.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Iversen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WA</Initials>
                  <FamilyName>See</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Armstrong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Wirth</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>97</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>247</FirstPage>
                <LastPage>254</LastPage>
                <Occurrence Type="PID">
                  <Handle>16430622</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2005.06051.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xit1amt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97(2):247–254.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_6">
              <CitationNumber>51.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yannucci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MB</Initials>
                  <FamilyName>Garnick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bhat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>176</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>520</FirstPage>
                <LastPage>525</LastPage>
                <Occurrence Type="PID">
                  <Handle>16813881</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2006.03.057</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176(2):520–525.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_6">
              <CitationNumber>52.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NL</Initials>
                  <FamilyName>Keating</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>O'Malley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>27</IssueID>
                <FirstPage>4448</FirstPage>
                <LastPage>4456</LastPage>
                <Occurrence Type="PID">
                  <Handle>16983113</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.06.2497</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtVyisrrK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24(27):4448–4456.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_6">
              <CitationNumber>53.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Sieber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Keiller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Kahnoski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gallo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>McFadden</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>171</VolumeID>
                <IssueID>6 Pt 1</IssueID>
                <FirstPage>2272</FirstPage>
                <LastPage>2276</LastPage>
                <Occurrence Type="PID">
                  <Handle>15126801</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000127738.94221.da</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkvVWhsrg%3D</Handle>
                </Occurrence>
                <BibComments>quiz</BibComments>
              </BibArticle>
              <BibUnstructured>Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171(6 Pt 1):2272–2276, quiz.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_6">
              <CitationNumber>54.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Goode</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Zietman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FJ</Initials>
                  <FamilyName>McGovern</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Finkelstein</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>2546</FirstPage>
                <LastPage>2553</LastPage>
                <Occurrence Type="PID">
                  <Handle>15226323</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.01.174</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWks7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22(13):2546–2553.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_6">
              <CitationNumber>55.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Blumenstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Loehrer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Bilateral orchiectomy with or without flutamide for metastatic prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>339</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>1036</FirstPage>
                <LastPage>1042</LastPage>
                <Occurrence Type="PID">
                  <Handle>9761805</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199810083391504</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmvV2itr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15):1036–1042.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_6">
              <CitationNumber>56.</CitationNumber>
              <BibArticle>
                <InstitutionalAuthorName>Prostate Cancer Trialists’ Collaborative Group</InstitutionalAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>355</VolumeID>
                <IssueID>9214</IssueID>
                <FirstPage>1491</FirstPage>
                <LastPage>1498</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(00)02163-2</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355(9214):1491–1498.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_6">
              <CitationNumber>57.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Fowler</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Pandey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LE</Initials>
                  <FamilyName>Seaver</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TP</Initials>
                  <FamilyName>Feliz</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>154</VolumeID>
                <IssueID>2 Pt 1</IssueID>
                <FirstPage>448</FirstPage>
                <LastPage>453</LastPage>
                <Occurrence Type="PID">
                  <Handle>7541862</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fowler JE, Jr., Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154(2 Pt 1):448–453.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_6">
              <CitationNumber>58.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Liebertz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mazumdar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Brett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Schwartz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Bicalutamide for advanced prostate cancer: the natural versus treated history of disease</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>2928</FirstPage>
                <LastPage>2938</LastPage>
                <Occurrence Type="PID">
                  <Handle>9256137</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXls1SmurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15(8):2928–2938.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_6">
              <CitationNumber>59.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Joyce</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Fenton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Rode</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Constantine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Gaynes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Kolvenbag</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>159</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>149</FirstPage>
                <LastPage>153</LastPage>
                <Occurrence Type="PID">
                  <Handle>9400459</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)64039-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmsFOiurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159(1):149–153.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_6">
              <CitationNumber>60.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>149</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>607</FirstPage>
                <LastPage>609</LastPage>
                <Occurrence Type="PID">
                  <Handle>7679759</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s7nt1Cnug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149(3):607–609.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_6">
              <CitationNumber>61.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Dupont</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gomez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Cusan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Koutsilieris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Labrie</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>150</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>908</FirstPage>
                <LastPage>913</LastPage>
                <Occurrence Type="PID">
                  <Handle>7688437</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szkslentw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150(3):908–913.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_6">
              <CitationNumber>62.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Carroll</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>43</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>408</FirstPage>
                <LastPage>410</LastPage>
                <Occurrence Type="PID">
                  <Handle>7510915</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0090-4295(94)90092-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c7ot1ehug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43(3):408–410.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_6">
              <CitationNumber>63.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PT</Initials>
                  <FamilyName>Nieh</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Withdrawal phenomenon with the antiandrogen casodex</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>153</VolumeID>
                <IssueID>3 Pt 2</IssueID>
                <FirstPage>1070</FirstPage>
                <LastPage>1072</LastPage>
                <Occurrence Type="PID">
                  <Handle>7531785</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M7ls1KlsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol 1995; 153(3 Pt 2):1070–1072.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_6">
              <CitationNumber>64.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PF</Initials>
                  <FamilyName>Schellhammer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Venner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Haas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PT</Initials>
                  <FamilyName>Nieh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Seabaugh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>157</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>1731</FirstPage>
                <LastPage>1735</LastPage>
                <Occurrence Type="PID">
                  <Handle>9112515</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)64846-8</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmtVGjtrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157(5):1731–1735.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_6">
              <CitationNumber>65.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Huan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Gerridzen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Yau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Stewart</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Antiandrogen withdrawal syndrome with nilutamide</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>49</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>632</FirstPage>
                <LastPage>634</LastPage>
                <Occurrence Type="PID">
                  <Handle>9111642</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(96)00558-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s3msFOntw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huan SD, Gerridzen RG, Yau JC, Stewart DJ. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49(4):632–634.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_6">
              <CitationNumber>66.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AO</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Parab</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Fontana</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>112</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>2393</FirstPage>
                <LastPage>2400</LastPage>
                <Occurrence Type="PID">
                  <Handle>18383517</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.23473</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnsFGjur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112(11):2393–2400.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_6">
              <CitationNumber>67.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Cooper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Weinberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Headlee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Thibault</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Tompkins</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>86</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>222</FirstPage>
                <LastPage>227</LastPage>
                <Occurrence Type="PID">
                  <Handle>7506794</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/86.3.222</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c7htFWmuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst 1994; 86(3):222–227.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_6">
              <CitationNumber>68.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NA</Initials>
                  <FamilyName>Dawson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Stadler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BI</Initials>
                  <FamilyName>Rini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Picus</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1025</FirstPage>
                <LastPage>1033</LastPage>
                <Occurrence Type="PID">
                  <Handle>15020604</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.06.037</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXptlCkurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22(6):1025–1033.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_6">
              <CitationNumber>69.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TH</Initials>
                  <FamilyName>Kwast</FamilyName>
                  <Particle>van der</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Schalken</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Ruizeveld</FamilyName>
                  <Particle>de Winter</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Vroonhoven</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Mulder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Boersma</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Androgen receptors in endocrine-therapy-resistant human prostate cancer</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>48</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>189</FirstPage>
                <LastPage>193</LastPage>
                <Occurrence Type="PID">
                  <Handle>1708363</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.2910480206</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991; 48(2):189–193.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_6">
              <CitationNumber>70.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Holzbeierlein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>LaTulippe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Satagopan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>164</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>217</FirstPage>
                <LastPage>227</LastPage>
                <Occurrence Type="PID">
                  <Handle>14695335</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)63112-4</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlsVCnsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164(1):217–227.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_6">
              <CitationNumber>71.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Ford</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Weaver</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Petrusz</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">The androgen axis in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>440</FirstPage>
                <LastPage>448</LastPage>
                <Occurrence Type="PID">
                  <Handle>14760063</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-1146-03</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXovVGktA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mohler JL, Gregory CW, Ford OH, III, Kim D, Weaver CM, Petrusz P et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440–448.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_6">
              <CitationNumber>72.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Stanbrough</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TR</Initials>
                  <FamilyName>Golub</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Rubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Penning</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>2815</FirstPage>
                <LastPage>2825</LastPage>
                <Occurrence Type="PID">
                  <Handle>16510604</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-05-4000</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhvV2gt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66(5):2815–2825.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_6">
              <CitationNumber>73.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Montgomery</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Mostaghel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Hess</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TF</Initials>
                  <FamilyName>Kalhorn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>4447</FirstPage>
                <LastPage>4454</LastPage>
                <Occurrence Type="PID">
                  <Handle>18519708</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-08-0249</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmsFKlsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68(11):4447–4454.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_6">
              <CitationNumber>74.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakabayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Regan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Lifsey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>96</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>783</FirstPage>
                <LastPage>786</LastPage>
                <Occurrence Type="PID">
                  <Handle>16153200</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2005.05714.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 2005; 96(6):783–786.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_6">
              <CitationNumber>75.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Okihara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Miyake</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Fujisawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Miyoshi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Matsumoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>180</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>921</FirstPage>
                <LastPage>927</LastPage>
                <Occurrence Type="PID">
                  <Handle>18635218</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2008.05.045</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtVKmsbjK</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180(3):921–927.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_6">
              <CitationNumber>76.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Visakorpi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Hyytinen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Koivisto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Tanner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Keinanen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Palmberg</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">In vivo amplification of the androgen receptor gene and progression of human prostate cancer</ArticleTitle>
                <JournalTitle>Nat Genet</JournalTitle>
                <VolumeID>9</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>401</FirstPage>
                <LastPage>406</LastPage>
                <Occurrence Type="PID">
                  <Handle>7795646</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ng0495-401</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXkvV2jurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9(4):401–406.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_6">
              <CitationNumber>77.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TD</Initials>
                  <FamilyName>Shuster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Frantz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AE</Initials>
                  <FamilyName>Spooner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GK</Initials>
                  <FamilyName>Ogata</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>332</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>1393</FirstPage>
                <LastPage>1398</LastPage>
                <Occurrence Type="PID">
                  <Handle>7723794</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199505253322101</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmvVWnsbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332(21):1393–1398.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_6">
              <CitationNumber>78.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CD</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Welsbie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Tran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Baek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Molecular determinants of resistance to antiandrogen therapy</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>33</FirstPage>
                <LastPage>39</LastPage>
                <Occurrence Type="PID">
                  <Handle>14702632</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm972</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10(1):33–39.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_6">
              <CitationNumber>79.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Dehm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>281</VolumeID>
                <IssueID>38</IssueID>
                <FirstPage>27882</FirstPage>
                <LastPage>27893</LastPage>
                <Occurrence Type="PID">
                  <Handle>16870607</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M605002200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XpsFOrtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 2006; 281(38):27882–27893.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_6">
              <CitationNumber>80.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Fenton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TD</Initials>
                  <FamilyName>Shuster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Fertig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Kolvenbag</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Functional characterization of mutant androgen receptors from androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>3</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1383</FirstPage>
                <LastPage>1388</LastPage>
                <Occurrence Type="PID">
                  <Handle>9815822</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXls1Smt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3(8):1383–1388.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_6">
              <CitationNumber>81.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Geller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Albert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Nachtsheim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Loza</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>132</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>693</FirstPage>
                <LastPage>696</LastPage>
                <Occurrence Type="PID">
                  <Handle>6471215</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3pt1GnsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984; 132(4):693–696.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_6">
              <CitationNumber>82.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Titus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Schell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FB</Initials>
                  <FamilyName>Lih</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KB</Initials>
                  <FamilyName>Tomer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>4653</FirstPage>
                <LastPage>4657</LastPage>
                <Occurrence Type="PID">
                  <Handle>16000557</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-0525</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlvVGhtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11(13):4653–4657.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_6">
              <CitationNumber>83.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Ettinger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Sobel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TG</Initials>
                  <FamilyName>Whitmore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Akbari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Bradley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Gleave</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2212</FirstPage>
                <LastPage>2221</LastPage>
                <Occurrence Type="PID">
                  <Handle>15026365</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-2148-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXitFCgu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004; 64(6):2212–2221.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_6">
              <CitationNumber>84.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Attard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Reid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Yap</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Raynaud</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Dowsett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Settatree</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>28</VolumeID>
                <IssueID>26</IssueID>
                <FirstPage>4563</FirstPage>
                <LastPage>4571</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.15.9749</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28):4563–4571.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_6">
              <CitationNumber>85.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>He</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RT</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FS</Initials>
                  <FamilyName>French</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>4315</FirstPage>
                <LastPage>4319</LastPage>
                <Occurrence Type="PID">
                  <Handle>11389051</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXktlSquro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61(11):4315–4319.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_6">
              <CitationNumber>86.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IU</Initials>
                  <FamilyName>Agoulnik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Vaid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Alvarado</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Bingman</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Erdem</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>10594</FirstPage>
                <LastPage>10602</LastPage>
                <Occurrence Type="PID">
                  <Handle>17079484</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-06-1023</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhtFGjsrfL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, III, Erdem H et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006; 66(21):10594–10602.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_6">
              <CitationNumber>87.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HG</Initials>
                  <FamilyName>Yoon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZQ</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Fondell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Qin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1</ArticleTitle>
                <JournalTitle>EMBO J</JournalTitle>
                <VolumeID>22</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1336</FirstPage>
                <LastPage>1346</LastPage>
                <Occurrence Type="PID">
                  <Handle>12628926</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/emboj/cdg120</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXit1yrsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J et al. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J 2003; 22(6):1336–1346.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_6">
              <CitationNumber>88.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Guenther</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WS</Initials>
                  <FamilyName>Lane</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Fischle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Verdin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Lazar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Shiekhattar</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness</ArticleTitle>
                <JournalTitle>Genes Dev</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1048</FirstPage>
                <LastPage>1057</LastPage>
                <Occurrence Type="PID">
                  <Handle>10809664</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjsVyrtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, Shiekhattar R. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 2000; 14(9):1048–1057.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_6">
              <CitationNumber>89.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Baek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Ohgi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Rose</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EH</Initials>
                  <FamilyName>Koo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Glass</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Rosenfeld</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>110</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>55</FirstPage>
                <LastPage>67</LastPage>
                <Occurrence Type="PID">
                  <Handle>12150997</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0092-8674(02)00809-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XlsV2mt70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 2002; 110(1):55–67.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_6">
              <CitationNumber>90.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Perissi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Aggarwal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Glass</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Rose</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Rosenfeld</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>116</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>511</FirstPage>
                <LastPage>526</LastPage>
                <Occurrence Type="PID">
                  <Handle>14980219</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0092-8674(04)00133-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhvVKru7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004; 116(4):511–526.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_6">
              <CitationNumber>91.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Baek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Ohgi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Welsbie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Sawyers</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>103</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>3100</FirstPage>
                <LastPage>3105</LastPage>
                <Occurrence Type="PID">
                  <Handle>16492776</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0510842103</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XksF2ksbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Baek SH, Ohgi KA, Nelson CA, Welsbie D, Chen C, Sawyers CL et al. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A 2006; 103(9):3100–3105.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_6">
              <CitationNumber>92.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Salvati</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Balog</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DD</Initials>
                  <FamilyName>Wei</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Pickering</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Attar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Geng</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1, 3(2H)-dione nucleus</ArticleTitle>
                <JournalTitle>Bioorg Med Chem Lett</JournalTitle>
                <VolumeID>15</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>389</FirstPage>
                <LastPage>393</LastPage>
                <Occurrence Type="PID">
                  <Handle>15603960</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.bmcl.2004.10.051</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtFanu7nJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Salvati ME, Balog A, Wei DD, Pickering D, Attar RM, Geng J et al. Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. Bioorg Med Chem Lett 2005; 15(2):389–393.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_6">
              <CitationNumber>93.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Schayowitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Sabnis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VC</Initials>
                  <FamilyName>Njar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Brodie</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>121</FirstPage>
                <LastPage>132</LastPage>
                <Occurrence Type="PID">
                  <Handle>18202015</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1535-7163.MCT-07-0581</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmsVyhsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schayowitz A, Sabnis G, Njar VC, Brodie AM. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther 2008; 7(1):121–132.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_6">
              <CitationNumber>94.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>101</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1084</FirstPage>
                <LastPage>1089</LastPage>
                <Occurrence Type="PID">
                  <Handle>18399827</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2008.07509.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmtlSktL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 2008; 101(9):1084–1089.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
